Disease · EFO_1000869
chronic interstitial cystitis
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. chronic interstitial cystitis. Diseases, record EFO_1000869. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_1000869
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
Cystitis, Interstitial, IC/BPS, IC/PBS, Interstitial cystitis, bladder pain syndrome, chronic interstitial cystitis (disorder), chronic interstitial cystitis (disorder) [Ambiguous], chronic interstitial cystitis NOS (disorder), interstitial cystitis, chronic, interstitial cystitis/bladder pain syndrome, interstitial cystitis/painful bladder syndrome, painful bladder syndrome, ulcerative cystitis
- Open Targets
- Highest stage of its drugs
- Approval, for 2 of its 49 drugs, from EMA Human Drugs, PMDA and TTD
- Open Targets
Drugs49
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DIMETHYL SULFOXIDE | CHEMBL504 | Small molecule | Approval | PMDA | 5 | 4 | 3 | Drugs and targets |
| PENTOSAN POLYSULFATE SODIUM | CHEMBL1201516 | Small molecule | Approval | EMA Human Drugs and TTD | 4 | 1 | 1 | Drugs and targets |
| AMITRIPTYLINE | CHEMBL629 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| GABAPENTIN | CHEMBL940 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ROSIPTOR | CHEMBL3989954 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ADALIMUMAB | CHEMBL1201580 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CERTOLIZUMAB PEGOL | CHEMBL1201831 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ESTROGENS, CONJUGATED | CHEMBL1201649 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets | |
| METHENAMINE | CHEMBL1201270 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MIRABEGRON | CHEMBL2095212 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 49
See all 49 drugsTargets61
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| SCN4A | Sodium channel alpha subunit | 3 | Sodium channel alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6329 | Drugs and targets |
| SNAP25 | Synaptosomal-associated protein 25 | 3 | Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme; Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor | Phase 2 | https://conductscience.org/library/genes/6616 | Drugs and targets |
| ESR2 | Estrogen receptor | 2 | Estrogen receptor agonist; Estrogen receptor beta agonist | Phase 3 | https://conductscience.org/library/genes/2100 | Drugs and targets |
| NGF | Beta-nerve growth factor | 2 | Beta-nerve growth factor inhibitor | Phase 2 | https://conductscience.org/library/genes/4803 | Drugs and targets |
| OPRM1 | Mu-type opioid receptor | 2 | Mu opioid receptor agonist; Opioid receptors; mu/kappa/delta antagonist | Phase 2 | https://conductscience.org/library/genes/4988 | Drugs and targets |
| PTGS1 | Cyclooxygenase | 2 | Cyclooxygenase inhibitor | Unknown | https://conductscience.org/library/genes/5742 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 2 | Cyclooxygenase inhibitor | Unknown | https://conductscience.org/library/genes/5743 | Drugs and targets |
| SCN10A | Sodium channel alpha subunit | 2 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6336 | Drugs and targets |
| SCN11A | Sodium channel alpha subunit | 2 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/11280 | Drugs and targets |
| SCN1A | Sodium channel alpha subunit | 2 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6323 | Drugs and targets |
1 to 10 of 61
See all 61 targetsTrials56
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 5 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00086684 | Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis | Phase 4 | 369 | 2012-07-06 | Interstitial Cystitis | PENTOSAN POLYSULFATE SODIUM | Its record names the disease | ClinicalTrials.gov |
| NCT00295854 | Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis | Phase 2 | 296 | 2012-01-19 | Interstitial Cystitis | TIPELUKAST | Its record names the disease | ClinicalTrials.gov |
| NCT00124306 | Efficacy of Amitriptyline for Painful Bladder Syndrome (PBS) | Phase 3 | 271 | 2025-10-07 | Bladder Diseases, Interstitial Cystitis | AMITRIPTYLINE | Its record names the disease | ClinicalTrials.gov |
| NCT02411110 | A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome | Phase 2 | 131 | 2018-01-04 | Cystitis, Interstitial, Painful Bladder Syndrome | LIDOCAINE | Its record names the disease | ClinicalTrials.gov |
| NCT01569438 | The Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Female Participants With Interstitial Cystitis /Bladder Pain Syndrome (MK-7264-005) | Phase 2 | 107 | 2017-01-12 | Bladder Pain Syndrome | GEFAPIXANT | Its record names the disease | ClinicalTrials.gov |
| NCT01475253 | Double-Blind Placebo Controlled Study of Safety,Tolerability, and Efficacy of LiRIS® in Women With Interstitial Cystitis | Phase 2 | 104 | 2015-09-21 | Interstitial Cystitis | LIDOCAINE | Its record names the disease | ClinicalTrials.gov |
| NCT02591199 | Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome | Phase 2 | 91 | 2026-02-03 | Interstitial Cystitis, Bladder Pain Syndrome | HEPARIN SODIUM, LIDOCAINE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT03463915 | Clinical Trial Comparing Two Bladder Instillations for IC/BPS | Phase 3 | 90 | 2021-09-01 | Interstitial Cystitis, Bladder Pain Syndrome | TRIAMCINOLONE ACETONIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01882543 | Efficacy and Safety of AQX-1125 in IC/BPS | Phase 2 | 69 | 2017-09-05 | Interstitial Cystitis, Bladder Pain Syndrome | ROSIPTOR | Its record names the disease | ClinicalTrials.gov |
| NCT00601484 | An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis | Phase 2 | 65 | 2021-05-13 | Cystitis, Interstitial | TANEZUMAB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 56
See all 56 trialsComparisons in its trials25
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| 1 - Amitriptyline vs 2 - Placebo: deaths from any cause | 0 of 135 | 0 of 136 | 271 | NCT00124306 | Trial comparisons |
| 1 - Amitriptyline vs 2 - Placebo: serious adverse events | 2 of 135 | 3 of 136 | 271 | NCT00124306 | Trial comparisons |
| Gefapixant vs Placebo: deaths from any cause | 0 of 55 | 0 of 52 | 107 | NCT01569438 | Trial comparisons |
| Gefapixant vs Placebo: serious adverse events | 0 of 54 | 0 of 51 | 105 | NCT01569438 | Trial comparisons |
| Bladder Instillation WITH Triamcinolone Acetonide vs Bladder Instillation WITHOUT Triamcinolone Acetonide: Number of Participants With at Least One Adverse Event | 1 of 45 | 5 of 45 | 90 | NCT03463915 | Trial comparisons |
| Bladder Instillation WITH Triamcinolone Acetonide vs Bladder Instillation WITHOUT Triamcinolone Acetonide: deaths from any cause | 0 of 45 | 0 of 45 | 90 | NCT03463915 | Trial comparisons |
| Bladder Instillation WITH Triamcinolone Acetonide vs Bladder Instillation WITHOUT Triamcinolone Acetonide: serious adverse events | 0 of 45 | 0 of 45 | 90 | NCT03463915 | Trial comparisons |
Bladder Instillation WITH Triamcinolone Acetonide vs Bladder Instillation WITHOUT Triamcinolone Acetonide: Sexual Function Measured by the Pelvic Organ Prolapse Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR) Questionnaire | 4 of 36 | 4 of 40 | 76 | NCT03463915 | Trial comparisons |
| AQX-1125 vs Placebo: serious adverse events | 0 of 37 | 0 of 32 | 69 | NCT01882543 | Trial comparisons |
| Tanezumab vs Placebo: Number of Participants With Clinically Significant Change From Baseline in Vital Signs | 0 of 34 | 0 of 30 | 64 | NCT00601484 | Trial comparisons |
1 to 10 of 25
See all 25 comparisons in its trialsPapers from its trials19
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_1000869
GET https://conductscience.org/api/diseases/v1/EFO_1000869/drugs?page=2